An observational study in Interstitial Lung Disease, Sarcoidosis and Idiopathic Pulmonary Fibrosis, sponsored by University of Kansas Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by University of Kansas Medical Center · Observational
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
The University of Kansas ILD and Rare Lung Disease clinic sees hundreds of new patients per year. The investigators would like to leverage this resource to develop an Interstitial Lung Disease Research Unit (ILDRU) repository and database to help develop new methods for early diagnosis, uncover underlying genetic and environmental risk factors, as well as potential treatment targets in the broad range of interstitial lung diseases and rare lung diseases (RLD).
Patients with ILD, RLD and subjects at risk for ILD
Inclusion Criteria:
Collect clinically obtained data for patients with ILD, RLD and risk for ILD/RLD to support research.
Time frame: Enrollment to Year 10
Establish a collection of biological samples from patients with ILD, RLD and subjects at risk for ILD.
Time frame: Enrollment to Year 10
Correlate biological samples with individual longitudinal clinical data.
Time frame: Enrollment to Year 10
Provide biological samples to researchers performing studies in ILD and RLD.
Time frame: Enrollment to Year 10
Collect historical data and imaging from deceased patients with ILD.
Time frame: Enrollment to Year 10
Plan to share: Yes — Contact Kimberly Lovell to discuss accessing IPD
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Kansas Medical Center